Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 245-254

  Clary, Audrey ^b   Larrue, Annick ^b   Pourquier, Philippe ^b   Robert, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NONE

Author keywords

Amsacrine; c myc; Doxorubicin; K562; Topoisomerase II

Indexed keywords

AMSACRINE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN;

APOPTOSIS; ARTICLE; DNA NICK TRANSLATION; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG EFFECT; ERYTHROLEUKEMIA CELL; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

EID: 0031946082     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00007     Document Type: Article

References (38)

1. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681-95.
2. Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer 1992; 28A: 2055-60.
3. Gewirtz D. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol 1991; 42: 2253-8.
4. Pommier Y, Capranico G, Orr A, Kohn K. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs. J Mol Biol 1991; 222: 909-24.
5. Riou JF, Villarem MJ, Larsen CJ, Riou G. In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene. Biochem Biophys Res Commun 1986; 137: 154-60.
6. Riou JF, Lefevre D, Riou G. Stimulation of the topoisomerase II-induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression. Biochemistry 1989; 28: 9104-10.
7. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA, Gewirtz DA. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol 1994; 47: 317-29.
8. Orr MS, Fornari FA, Randolph JK, Gewirtz DA. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Biochim Biopbys Acta 1995; 1262: 139-45.
9. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the mutidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
10. De Isabella P, Capranico G, Zunino F. The role of topoisomerasc II in drug resistance. Life Sci 1991; 48: 2195-205.
11. Pourquier P, Montaudon D, Huet S, Larrue A, Clary A, Robert J. Doxorubicin-induced alteration of c-myc and c-jun gene expression in rat glioblastoma cells: role of c-jun in drug resistance and cell death. Biochem Pharmacol 1997: in press.
12. Oshita F, Saijo N. Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines. Jpn J Cancer Res 1994; 85: 669-73.
13. Gazin C, Dupont de Dinechin S, Hampe A, et al. Nucleotide sequence of the human c-myc locus: provocative open reading frame within the first exon. EMBO J 1984; 3: 383-7.
14. Lozzio CB, Lozzio BB. Chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-34.
15. Tsuruo T, Iida-Saito H, Kawabata II, Oh-Hara T, Hamada H, Utakoji T. Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 1986; 77: 682-92.
16. Carmichael J, de Graaf WG, Gazdar AF, Mina JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
17. Modjtahedi N, Lavialle C, Poupon MF, et al. Increased level of amplification of the c-myc oncogene in tumors induced in nude mice by a human breast carcinoma cell line. Cancer Res 1985; 45: 4372-9.
18. Moos M, Gallwitz D. Structure of two human β-actin-related processed genes one of which is located next to a simple repetitive sequence. EMBO J 1983; 2: 757-61.
19. Glisin V, Crkvenjakov R, Byus C. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry 1974; 13: 2633-40.
20. Kim R, Beck WT. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of jun/fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26. Cancer Res 1994; 54: 4958-66.
21. Drake FH, Zimmermann JP, McCabe FL, et al. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. J Biol Chem 1987; 262: 16739-47.
22. Laemmli UK. Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature 1970; 227: 680-5.
23. Fan S, El-Deiry WS, Bae I, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994; 54: 5824-30.
24. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference with DNA unwinding by doxorubicin in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45: 649-56.
25. Liu LF, Rowe TC, Yang L, Tewey M, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 1983; 258: 15365-70.
26. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA, Gewirtz DA. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol 1994; 47: 317-29.
27. Gewirtz DA, Orr MS, Fornari FA, et al. Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line. Evidence for induction of gene-specific damage and alterations in gene expression, Cancer Res 1993; 53: 3547-54.
28. Mangasarian K, Mellon WS. 1,25-dihydroxyvitamin D-3 destabilizes c-myc mRNA in HL-60 leukemic cells. Biochim Biophys Acta 1993; 1172: 55-63.
29. Dani C, Blanchard JM, Piechaczyk M, El Sabouty S, Marty L, Jeanteur P. Proc Nutl Acad Sci USA 1984; 81: 7046-50.
30. Brewer G, Ross J. Regulation of c-myc mRNA stability in uitro by a labile destabilizer with an essential nucleic acid component. Mol Cell Biol 1989; 9: 1996-2006.
31. Pommier Y, Orr A, Kohn KW, Riou JF. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res 1992; 52: 3125-30.
32. Spitzner JR, Muller MT. A consensus sequence for cleavage by vertebrate DNA topoisomerase II. Nucleic Acid Res 1988; 16: 5533-56.
33. Ritke MK, Yalowich JC. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 1993; 46: 2007-20.
34. Ogretmen B, Sofa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug-resistant MCF-7/Adr human breast cancer cells. Oncogene 1997; 14: 499-506.
35. Sinha BK, Yamazaki H, Eliot HM, Schneider E, Borner MM, O'Connor PM. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim Biophys Acta 1995; 1270: 12-8.
36. Ritke MK, Rusnak JM, Lazo JS, et al. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol 1994; 46: 605-11.
37. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995; 9: 1013-24.
38. Benito A, Grillot D, Nunez G, Fernandez-Luna JL. Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am J Pathol 1995; 146: 481-90.